Oncolytics Biotech (ONC.TO) Stock Price
Oncolytics Biotech Price
Oncolytics Biotech stock price
Oncolytics Biotech business model & stock analysis
Frequently asked questions about Oncolytics Biotech
The business model of Oncolytics Biotech Inc revolves around developing and commercializing immune-oncology virus-based therapies for the treatment of cancer. By utilizing its proprietary platform technology, the company aims to target and destroy cancer cells without harming normal healthy cells. Oncolytics Biotech's innovative approach involves using genetically modified viruses to selectively infect and replicate within cancer cells, resulting in their destruction. This targeted therapy is designed to stimulate the immune system's response to better fight against cancer cells. Oncolytics Biotech Inc's business model focuses on advancing its therapy candidates through clinical trials, seeking regulatory approvals, and ultimately providing effective treatments to cancer patients.
Oncolytics Biotech Inc primarily operates in the biotechnology industry.
The main competitors of Oncolytics Biotech Inc in the market include companies like Amgen Inc., Roche Holding AG, and Pfizer Inc.
Oncolytics Biotech Inc is a renowned biotechnology company specializing in the development of innovative cancer therapeutics. Founded in 1998, the company has a rich history and is headquartered in Calgary, Canada. Oncolytics Biotech focuses on harnessing the power of viruses to selectively target and destroy cancer cells without harming healthy tissues. Their flagship product, REOLYSIN®, is a proprietary formulation of the reovirus, which has shown promising results in clinical trials for a variety of cancer types. The company's dedication to research and development has positioned them as a leader in the field of oncolytic viruses, offering hope for effective cancer treatments in the future.
Oncolytics Biotech Inc has achieved several significant milestones in its journey. The company successfully received FDA Fast Track Designation for its lead product candidate, REOLYSIN, which is being developed for the treatment of metastatic breast cancer. Oncolytics Biotech also obtained Orphan Drug Designation for REOLYSIN from the FDA for the treatment of pancreatic cancer. Additionally, the company has entered into various strategic collaborations and partnerships to advance its oncology research and development initiatives. These achievements highlight Oncolytics Biotech's commitment to bringing innovative treatments to patients, particularly in the field of cancer therapy.
Oncolytics Biotech Inc is primarily present in Canada and the United States.
Oncolytics Biotech Inc represents values of innovation, dedication, and patient-centricity. With a corporate philosophy focused on developing targeted and cutting-edge therapies, Oncolytics Biotech is committed to advancing the field of oncolytic viruses for the treatment of cancer. The company's research and development efforts aim to provide patients with safe and effective treatments that harness the power of viruses to selectively destroy cancer cells while sparing healthy tissue. By constantly pushing the boundaries of science and seeking collaborations with experts in the field, Oncolytics Biotech strives to improve outcomes and quality of life for patients worldwide.
8 analysts currently rate the Oncolytics Biotech stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Oncolytics Biotech to generate revenue of 1.20 M CAD and earnings per share of -0.35 CAD.
Converted at the current exchange rate, the Oncolytics Biotech share trades at 0.89 EUR (1.42 CAD).
The Oncolytics Biotech share (ONC.TO) is listed on 3 stock exchanges, including: NASDAQ (ONCY), Toronto (ONC.TO), Frankfurt (ONYN.F).
Oncolytics Biotech is a Canadian company specializing in the development of virotherapeutic treatments for cancer. The company uses specially modified viruses to selectively destroy cancer cells. Oncolytics Biotech operates in the areas of research, development, manufacturing, and marketing. Its main product line is REOLYSIN®, an oncolytic virus that targets and destroys cancer cells in the body. The company aims to expand its portfolio of oncolytic viruses through continuous research and development projects. It collaborates with universities and research institutions worldwide to access important insights and advancements in cancer research. Oncolytics Biotech distributes and markets its biopharmaceutical products primarily through partnerships with pharmaceutical companies both domestically and internationally. The company has also carried out a strategic acquisition of TMG Biosciences to enhance its research capabilities and expand its oncolytic virus portfolio. Overall, Oncolytics Biotech's mission is to defeat cancer through innovative therapeutic approaches, offering a promising new therapy option for cancer patients worldwide.
The expected revenue of Oncolytics Biotech is 1.20 M CAD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Oncolytics Biotech is -26.54 M CAD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Oncolytics Biotech is currently -4.09. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Oncolytics Biotech stock.
The price-to-sales ratio (P/S) of Oncolytics Biotech is currently 90.50. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Oncolytics Biotech stock.
The Eulerpool Quality Score for Oncolytics Biotech is 2/10.
The ISIN of Oncolytics Biotech is CA6823108759. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Oncolytics Biotech is A2JMW5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Oncolytics Biotech is ONC.TO. The ticker symbol is used to trade Oncolytics Biotech shares on the stock exchange.
Oncolytics Biotech stock
Oncolytics Biotech Peer Group
Oncolytics Biotech Ticker
Oncolytics Biotech FIGI
All fundamentals and in-depth analysis of Oncolytics Biotech
Our stock analysis for Oncolytics Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncolytics Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.